Galapagos publishes 2022 annual report and announces Annual Shareholders’ Meeting
March 23 2023 - 4:01PM
Galapagos publishes 2022 annual report and announces Annual
Shareholders’ Meeting
- Publication of annual
report for financial year 2022
- Annual
Shareholders’ Meeting
proposed resolutions
include
re-appointment
of Board members
and appointment
of new statutory
auditor
Mechelen, Belgium;
23 March
2023, 21.01
CET; regulated information – Galapagos NV
(Euronext & NASDAQ: GLPG) today
publishes its
annual report for the financial
year 2022 and
announces its
Annual
Shareholders’
Meeting,
to be held on Tuesday 25
April
2023, at
2:00 p.m. (CET), at the
registered office of the
company.
The annual report for the financial year 2022,
including a review of figures and performance, is available online
at https://www.glpg.com/financial-reports and can also be
downloaded as a PDF. Our annual 2022 Form 20-F filing with the
Securities and Exchange Commission (SEC) is available at
www.sec.gov/edgar.
Furthermore, Galapagos has the honor to invite
its shareholders, holders of subscription rights, Board members and
statutory auditor to its Annual Shareholders’ Meeting (“AGM”) that
will be held on Tuesday 25 April 2023, at 2:00 p.m. (CET), at the
company’s registered office.
The items on the agenda of the AGM include,
amongst other items: (i) the re-appointment of Mr. Peter Guenter as
non-executive independent director for a period of 4 years, and the
re-appointments of Mr. Daniel O’Day and Dr. Linda Higgins as
non-executive non-independent directors for a period of 4 years,
and (ii) the appointment of BDO, permanently represented by Ellen
Lombaerts, as the company’s new statutory auditor for a period of 3
years.
In order to be admitted to the AGM to be held on
25 April 2023, the holders of securities issued by the company must
comply with article 7:134 of the Belgian Code of Companies and
Associations and article 23 of the company’s Articles of
Association, as well as fulfill the formalities as described in the
convening notice. The convening notice and any other documents
pertaining to the AGM can be consulted on our website:
www.glpg.com/shareholders-meetings.
About
GalapagosGalapagos is a fully integrated biotechnology
company focused on discovering, developing, and commercializing
innovative medicines. We are committed to improving patients’ lives
worldwide by targeting diseases with high unmet needs. Our R&D
capabilities cover multiple drug modalities, including small
molecules and cell therapies. Our portfolio comprises discovery
through to commercialized programs in immunology, oncology, and
other indications. Our first medicine for rheumatoid arthritis and
ulcerative colitis is available in Europe and Japan. For additional
information, please visit www.glpg.com or follow us
on LinkedIn or Twitter.
Contacts
Media
relations |
Investor
relations |
Marieke
Vermeersch |
Sofie Van
Gijsel |
+32 479
490 603 |
+1 781 296
1143 |
|
|
Elisa
Chenailler |
Sandra
Cauwenberghs |
+41 79 853 33
54 |
+32 495 58 46
63 |
|
ir@glpg.com |
Hélène de
Kruijs |
|
+31 6
22463921 |
|
media@glpg.com |
|
Forward-looking statements
This release may contain forward-looking
statements. Such forward-looking statements are not guarantees of
future results. These statements speak only as of the date of
publication of this release. We expressly disclaim any obligation
to update any forward-looking statements in this release, unless
specifically required by law or regulation.
Disclaimer
The contents of our website, including the
annual report for the financial year 2022, and any other website
that may be accessed from our website, shall not be deemed
incorporated by reference in any filing under the Securities Act of
1933.
- Galapagos publishes 2022 annual report and announces Annual
Shareholders’ Meeting
Galapagos (LSE:GLPG)
Historical Stock Chart
From Jul 2024 to Aug 2024
Galapagos (LSE:GLPG)
Historical Stock Chart
From Aug 2023 to Aug 2024